Skip to main content
IntegraGen logo

IntegraGen — Investor Relations & Filings

Ticker · ALINT ISIN · FR0010908723 LEI · 969500CQD8K0BUIGDH55 PA Professional, scientific and technical activities
Open in API
Filings indexed 160 across all filing types
Latest filing 2017-02-03 Share Issue/Capital Cha…
Country FR France
Listing PA ALINT

About IntegraGen

https://integragen.com/

IntegraGen, an OncoDNA company, specializes in translating molecular research into clinical practice, with a primary focus on cancer genomics and rare genetic diseases. The company provides comprehensive genomic services, including Next-Generation Sequencing (NGS) and advanced bioinformatics analysis, to academic researchers, biopharmaceutical companies, and clinical research organizations. Operating from a CLIA/CAP-certified laboratory, IntegraGen is a key genomics partner for oncology clinical trials. Its core mission involves identifying novel genetic biomarkers to develop and commercialize molecular diagnostic tests, delivering interpretable genomic data to advance both research and patient care.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Share Issue/Capital Change Classification · 99% confidence The document is a press release announcing the successful completion of a capital increase ('augmentation de capital') for €3.7 million, reserved for specific investors. Key phrases include 'augmentation de capital', 'suppression du droit préférentiel de souscription', and details about the issuance of new shares and the use of proceeds for business development. This directly relates to fundraising and capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (5371 chars) is substantial enough to be the primary announcement, not just a brief RPA.
2017-02-03 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references Article 223-16 of the AMF General Regulation and provides a table comparing the total number of shares and voting rights as of January 31, 2017, and December 31, 2016. This type of regular disclosure regarding the total number of shares and voting rights is a specific regulatory requirement, often related to capital structure changes or mandatory periodic reporting. Among the provided codes, 'SHA' (Share Issue/Capital Change) is the closest fit as it deals directly with the composition of the share capital and voting rights, although 'RNS' (Regulatory Filings) could also apply if a more specific code wasn't available. Given the direct focus on the total number of shares and voting rights, SHA is the most precise classification for this mandatory capital structure disclosure.
2017-02-01 French
Rachat d'actions / Contrat de liquidité Information relative au contrat de liquidité
Capital/Financing Update Classification · 99% confidence The document is titled "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ" (Semi-annual Liquidity Contract Balance) and reports the status of shares and cash held under a liquidity contract as of December 31, 2016. This type of report, detailing the status of a liquidity agreement (often related to share buybacks or market making activities), is a specific financial disclosure. It is not a full Annual Report (10-K), an Earnings Release (ER), or a standard Interim Report (IR). It relates to capital management and share activity. Given the options, it most closely aligns with a specific financial disclosure related to capital structure or share management. Since it is a formal, periodic report on a specific financial arrangement (liquidity contract), and not a general announcement of a report (RPA/RNS), it should be classified based on its content. The content directly relates to the company's shares and cash reserves managed under a specific agreement, which touches upon capital/financing activities. However, the most precise category for reports detailing share transactions or capital structure changes is often related to share issues or financing. Since this is a report on the status of a liquidity contract (which often involves share transactions), and there isn't a perfect fit like 'Liquidity Report', I will evaluate the closest options. It is a periodic financial statement/report, but not a comprehensive IR or 10-K. It details the status of shares held for liquidity purposes. Given the options, 'Capital/Financing Update' (CAP) is plausible if the liquidity contract is viewed as a financing tool, but 'Transaction in Own Shares' (POS) is also relevant if the liquidity provider is executing buybacks. Since this is a *balance* report, not a transaction announcement, and it's a formal periodic filing, I will check if it fits 'NAV' (unlikely as it's not a fund) or 'AR' (too specific for a standalone audit). The document is a formal, periodic report detailing the status of shares and cash related to market stabilization/liquidity provision. This is a highly specific financial disclosure. Given the lack of a 'Liquidity Report' code, and its focus on the status of shares held, it is closest to a specific financial disclosure. If we consider the liquidity contract as a mechanism for managing share capital/market presence, 'CAP' (Capital/Financing Update) is a reasonable fit for a formal report on such a mechanism, or 'POS' if the focus is purely on the shares held. Since it's a balance sheet of the contract, not a transaction announcement, I lean towards a general financial report category. Given the options, and recognizing this is a formal, periodic financial disclosure about share holdings/cash reserves under a specific agreement, it is best classified as a specific financial report. Since it is a formal report detailing the status of shares and cash, and not a general announcement, I will classify it as a specific financial report. Given the options, and the focus on share count and cash balance under a contract, it is a specific financial disclosure. I will select 'CAP' as liquidity contracts are intrinsically linked to capital management and financing activities, even if periodic. The document length (1811 chars) confirms it is the report itself, not just an announcement.
2017-01-04 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 90% confidence The document is titled "FOR IMMEDIATE RELEASE" and details the presentation of new clinical data regarding IntegraGen's miR-31-3p biomarker at the 2016 ESMO Congress. It includes quotes from researchers and the CEO, discusses clinical trial results (FIRE-3), and announces future plans for a test availability. This format strongly suggests an announcement of scientific or business findings, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive quarterly report (IR). Since it is an announcement of data being presented at a medical conference, it functions as an Investor Presentation (IP) or a general press release about scientific progress. Given the focus on presenting data and strategy to investors/the public, 'Investor Presentation' (IP) is the most fitting category, although it is delivered via a press release format. It is not a formal presentation document itself, but it conveys the content typically found in one. Since there is no specific category for 'Scientific/Clinical Data Press Release', and it is not a formal regulatory filing, I will classify it as an Investor Presentation (IP) as it serves the purpose of informing the investment community about key scientific developments and future commercialization plans.
2016-10-10 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Investor Presentation Classification · 95% confidence The document is a press release announcing positive new data regarding the miR-31-3p biomarker presented at the 2016 ESMO congress. It details clinical findings, quotes key personnel (CEO, Professors), and discusses future commercialization plans for the test. This format—a formal announcement of scientific/clinical progress, often released outside of mandatory quarterly/annual filings—is characteristic of an Investor Presentation (IP) or a general press release detailing significant corporate/scientific updates. Since it is a detailed presentation of data and strategy aimed at investors, Investor Presentation (IP) is the most fitting category, as it is more specific than a general Regulatory Filing (RNS) or Earnings Release (ER). The length (6010 chars) suggests it is more substantial than a simple RPA.
2016-10-10 French
Communiqués au titre de l'obligation d'information permanente / Communiqué sur comptes, résultats, chiffres d’affaires
Earnings Release Classification · 98% confidence The document is titled 'COMMUNIQUE DE PRESSE' (Press Release) and immediately announces the 'Chiffre d'affaires au 1er semestre 2016' (Revenue for the first half of 2016). It provides key financial highlights (revenue figures, growth rates) and operational updates, characteristic of an initial results announcement. Crucially, the final line states: 'IntegraGen publiera ses résultats semestriels le 12 octobre 2016.' This indicates the current document is the preliminary announcement of results, not the comprehensive 'Interim/Quarterly Report' (IR) itself, which is scheduled for a later date. Therefore, it fits the definition of an Earnings Release (ER). H1 2016
2016-07-07 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.